JPH08133970A - Blood sugar increase inhibitor and its use - Google Patents
Blood sugar increase inhibitor and its useInfo
- Publication number
- JPH08133970A JPH08133970A JP6301675A JP30167594A JPH08133970A JP H08133970 A JPH08133970 A JP H08133970A JP 6301675 A JP6301675 A JP 6301675A JP 30167594 A JP30167594 A JP 30167594A JP H08133970 A JPH08133970 A JP H08133970A
- Authority
- JP
- Japan
- Prior art keywords
- sugar
- betaine
- blood sugar
- blood
- blood glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000000346 sugar Nutrition 0.000 title claims abstract description 63
- 210000004369 blood Anatomy 0.000 title claims abstract description 44
- 239000008280 blood Substances 0.000 title claims abstract description 44
- 239000003112 inhibitor Substances 0.000 title claims abstract description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 27
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960003237 betaine Drugs 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 235000013361 beverage Nutrition 0.000 abstract 1
- 235000019577 caloric intake Nutrition 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000036962 time dependent Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000208251 Gymnema Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238413 Octopus Species 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000208253 Gymnema sylvestre Species 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229930183009 gymnemic acid Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- -1 obesity Chemical class 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、糖質の過剰摂取に伴う
高血糖状態により引き起こされる疾患、例えば肥満症、
高脂血症、糖尿病などの予防または治療を目的とした健
康志向の製剤、食品素材又は飲食品に関わる。TECHNICAL FIELD The present invention relates to diseases caused by hyperglycemic conditions associated with excessive intake of carbohydrates, such as obesity,
It relates to health-conscious preparations, food materials or foods and drinks for the purpose of preventing or treating hyperlipidemia, diabetes and the like.
【0002】[0002]
【従来の技術】近年、他の先進国同様わが国でも飽食に
伴うカロリーの過剰摂取による肥満症、高脂血症、糖尿
病の罹病が問題として挙げられている。この疾患は心臓
病等の他の成人病とも深く関わると言われており、その
治療および予防は非常に重要な課題になっている。従来
の嗜好を満足させつつこれを解決する方法が求められ、
多岐にわたり研究が進められているのが現状である。2. Description of the Related Art In recent years, in Japan, as in other developed countries, obesity, hyperlipidemia, and diabetes caused by excessive intake of calories associated with satiety have been cited as problems. It is said that this disease is deeply related to other adult diseases such as heart disease, and its treatment and prevention have become very important issues. A method of solving this while satisfying the conventional taste is required,
The current situation is that a wide variety of research is being conducted.
【0003】これらに対する一つの予防または治療手段
としてカロリー源の供給量を減らすことが考えられる。
これに関し主なカロリー源のひとつである蔗糖などの糖
源に代わる低カロリー甘味料が開発されてきた。これら
は蔗糖と同様の甘味をもちながらはるかに低カロリーで
あるか、蔗糖よりも強い甘味によりその使用量が少なく
て良いため摂取カロリーを減らし得るものである。この
例としてエリスリトール、アスパルテーム等が提案され
ている。しかし、嗜好性、物理化学性、摂取制限などに
より、これら低カロリー甘味料または合成甘味料が広く
食品に利用されるには至っていない。As one of the preventive or therapeutic measures against these, it is considered to reduce the supply of calorie source.
In this regard, low-calorie sweeteners have been developed to replace sugar sources such as sucrose, which is one of the main calorie sources. They have a sweetness similar to that of sucrose and have a much lower calorie content, or they have a sweetness stronger than that of sucrose and thus can be consumed in a small amount because they can be used in a small amount. Erythritol, aspartame, etc. have been proposed as examples of this. However, these low-calorie sweeteners and synthetic sweeteners have not been widely used in foods because of their palatability, physicochemical properties, intake restrictions, and the like.
【0004】また一方、摂取後の糖質に対し、その消化
管からの吸収を抑制することにより、過剰な血糖値の上
昇による前述の疾患を防止または治療しようという試み
もなされてきた。そして、一般に人間が食している植
物、動物由来の食品中に、糖質の吸収を抑制する成分が
あることが明らかにされてきている。その例としてギム
ネマ・シルベスタ中のギムネマ酸(上野学、月刊フード
ケミカル,1993−12,pp.21−26)、L−
アラビノース、D−キシロースなどの単糖類(特開平6
−65080)、黒砂糖中の黒色物質(木村、大南、奥
田ら、薬学雑誌,Vol.102,pp.666−66
9,1982)、水溶性の食物繊維(奥恒行、食物繊
維、印南、桐山編、第一出版、pp.186−193,
1982)などがある。ギムネマ酸などの物質がどのよ
うなメカニズムで糖吸収を阻害・遅延するかについては
これら文献中に種々示唆されている。On the other hand, attempts have also been made to prevent or treat the above-mentioned diseases caused by excessive elevation of blood sugar level by suppressing absorption of sugar after ingestion from the digestive tract. In addition, it has been clarified that there is a component that suppresses the absorption of sugars in foods derived from plants and animals that are generally eaten by humans. Gymnema acid in Gymnema sylvestre (Ueno Manabu, Monthly Food Chemical, 1993-12, pp. 21-26), L-
Monosaccharides such as arabinose and D-xylose
-65080), black substance in brown sugar (Kimura, Onanami, Okuda et al., Pharmaceutical Journal, Vol. 102, pp. 666-66).
9, 1982), water-soluble dietary fiber (Oku Tsune, dietary fiber, Innan, Kiriyama ed., Daiichi Shuppan, pp.186-193.
1982). Various mechanisms have been suggested in these documents as to the mechanism by which substances such as gymnemic acid inhibit or delay sugar absorption.
【0005】また、奥田らはラットの空腸から調整した
腸小胞懸濁液を用いたin vitroの試験において
イカ、タコに含まれるベタイン化合物に腸管へのグルコ
ースの取り込みを抑制する働きがあることを報告してい
る(奥田拓道、食品工業,1993−7.30,pp.
18−26)。Further, Okuda et al. Have shown that betaine compounds contained in squid and octopus have a function of suppressing glucose uptake into the intestinal tract in an in vitro test using an intestinal vesicle suspension prepared from the jejunum of a rat. (Takudo Okuda, Food Industry, 1993-7.30, pp.
18-26).
【0006】[0006]
【問題点を解決するための手段】本発明者らは、天然に
存在する各種成分の中から、糖質負荷後の血糖値上昇抑
制効果を有する物質を検討し、その糖吸収の阻害・遅延
効果について実験動物を用いて詳細に研究した。その結
果、意外にも砂糖ダイコンに含まれるベタインにin
vivoにおいて顕著に血糖値上昇抑制作用があること
を見いだし、本発明を完成するに至った。[Means for Solving the Problems] The present inventors have investigated, among various naturally occurring components, a substance having an effect of suppressing an increase in blood glucose level after sugar loading, and inhibiting or delaying the sugar absorption thereof. The effect was studied in detail using experimental animals. As a result, the betaine contained in sugar beet was surprisingly in
It was found that there is a remarkable inhibitory effect on blood sugar level elevation in vivo, and the present invention has been completed.
【0007】本発明で用いるベタインは、例えば砂糖ダ
イコンから精製されるもので、グリシンが完全にN−メ
チル化されたものであり、次式で示されるものである。The betaine used in the present invention is, for example, purified from sugar beet, is glycine completely N-methylated, and is represented by the following formula.
【0008】[0008]
【化1】 Embedded image
【0009】本発明で使用するベタインは動植物界に広
く存在する物質で、動物では、エビ、カニ、タコ、イカ
などの水産物に、植物では、麦芽、キノコ類、果実、地
下茎特にアカザ科に多く含まれていることが知られてい
る。素材としては、ビート(砂糖ダイコン)から分離精
製される。ベタインは吸収後ジメチルグリシン、メチル
グリシンを経て無害のアミノ酸グリシンとなる。経口亜
急性毒性はLD50=18.7g/kgと極めて低く、実
質的に無害である。食品素材としては独特の甘味、うま
味の面から主に水産物を材料とする加工食品の天然調味
料として用いられている。飼料添加物としては成長促進
効果、脂質代謝・肝機能正常化効果をもつコリンの代替
品として世界で広く用いられている。The betaine used in the present invention is a substance widely existing in the animal and plant kingdoms, and in animals, it is often found in marine products such as shrimp, crab, octopus, and squid, and in plants, it is often found in malt, mushrooms, fruits and rhizomes, especially the rhizome family. It is known to be included. As a raw material, it is separated and refined from beet (sugar radish). Betaine becomes a harmless amino acid glycine through dimethylglycine and methylglycine after absorption. The oral subacute toxicity is extremely low with an LD 50 = 18.7 g / kg, and it is substantially harmless. As a food material, it is used as a natural seasoning for processed foods mainly made of marine products from the viewpoint of unique sweetness and umami. As a feed additive, it is widely used in the world as a substitute for choline, which has a growth promoting effect and a lipid metabolism / normal liver function normalizing effect.
【0010】本発明のベタインを有効成分とする血糖値
上昇抑制剤は、ベタイン粉末を散剤にするだけでもよい
が、飲みやすいように、結着剤やクエン酸、レモンフレ
ーバーなどと混合し、打錠しておくとよい。この散剤や
錠剤は食中、食後などの糖分摂取後に飲用するとよい。The blood sugar level elevation inhibitor of the present invention containing betaine as an active ingredient may be a powder of betaine powder, but it may be mixed with a binder, citric acid, lemon flavor or the like for easy drinking, You should lock it. It is advisable to take this powder or tablet after eating sugar such as during or after eating.
【0011】また、本発明の血糖値上昇抑制機能性糖質
食品素材は、一般に、砂糖、グルコース、液糖などの糖
質とベタインを混合しておくのがよい。ベタインの混合
は、糖質の0.1〜50%、好ましくは1〜30%、よ
り好ましくは3〜20%、更に好ましくは5〜18%程
度である。In addition, it is generally preferable to mix betaine with a sugar such as sugar, glucose, or liquid sugar in the food material for functional sugar food for suppressing blood sugar level increase of the present invention. The mixing ratio of betaine is 0.1 to 50% of the sugar, preferably 1 to 30%, more preferably 3 to 20%, further preferably 5 to 18%.
【0012】この本発明の血糖値上昇抑制機能性糖質食
品素材は、糖質のみよりむしろ美味であり、そのままコ
ーヒー、紅茶などの甘味料として使用することができる
し、また、各種食品の加工乃至は調理に用いて、甘味付
与の目的を十分にはたすことができ、かつ、血糖値上昇
抑制を行うことができるものである。本発明の食品素材
は経口摂取可能ないかなる形状においても使用可能であ
る。結晶で用いても、他の食品またはビタミン他の栄養
素、香料等と共に使用する事もできる。使用例として粉
末、結晶製品、インスタント粉末、タブレット、グラニ
ュール、炭酸タブレット、ペースト、ガム他があげられ
る。The functional sugar food material for suppressing blood sugar level elevation of the present invention is delicious rather than sugar alone, and can be used as it is as a sweetener for coffee, tea, etc., and can be used for processing various foods. Or, it can be used for cooking and can sufficiently fulfill the purpose of imparting sweetness and can suppress an increase in blood glucose level. The food material of the present invention can be used in any orally ingestible form. Even if it is used as a crystal, it can be used together with other foods, vitamins and other nutrients, flavors and the like. Examples of use include powders, crystalline products, instant powders, tablets, granules, carbonated tablets, pastes, gums and the like.
【0013】次に本発明の試験例及び実験例を示す。Next, test examples and experimental examples of the present invention will be shown.
【0014】[0014]
【実施例】【Example】
【0015】[0015]
【試験例1】ベタインの糖吸収抑制効果についてラット
を用いた耐糖性試験の方法を用いて調べた。同時に従来
糖吸収抑制効果があるといわれているペクチン、ギムネ
マについても比較した。10週令のWistar系雄ラ
ット32匹を1週間次の表1の基本飼料で予備飼育し試
験に用いた。予備飼育終了後24時間絶食し、8匹ずつ
4群に組分け、20%グルコース溶液を糖液とした次の
表2Test Example 1 The sugar absorption inhibitory effect of betaine was examined by the method of glucose tolerance test using rats. At the same time, we also compared pectin and Gymnema, which are said to have a sugar absorption inhibitory effect. 32 10-week-old male Wistar rats were preliminarily bred for 1 week with the basic diet shown in Table 1 below and used for the test. After fasting for 24 hours, the animals were fasted for 24 hours, 8 animals were divided into 4 groups, and a 20% glucose solution was used as a sugar solution.
【0016】[0016]
【表1】 [Table 1]
【0017】[0017]
【表2】 [Table 2]
【0018】の各投与液を1.25mL/100g体重
で経口投与し、0、15、30、60、120分後に尾
静脈より採血し、10,000r.p.m.、5分遠心
分離し血清を取りだし、グルコースオキシダーゼ法で血
清グルコース濃度(以下「血糖値」という)を分析し
た。また、血糖値の経時変化から0から120分までの
全血糖値上昇量を示す血糖値上昇面積を算出した。Each of the above administration solutions was orally administered in an amount of 1.25 mL / 100 g body weight, and blood was collected from the tail vein at 0, 15, 30, 60, and 120 minutes, and 10,000 r.p.m. p. m. The serum was taken out by centrifugation for 5 minutes, and the serum glucose concentration (hereinafter referred to as “blood glucose level”) was analyzed by the glucose oxidase method. Further, the blood glucose level rising area showing the total blood glucose level rising amount from 0 to 120 minutes was calculated from the time-dependent change in blood glucose level.
【0019】なお、血糖値上昇面積とは血糖値の経時変
化をグラフにした場合の血糖値変化の折れ線と、試験開
始時の血糖値を示す点を通り時間軸と平行な直線との間
の面積を指す。これは試験時間中の血糖値上昇の総和を
意味する(単位はmg/dL/120min)。ベタイ
ン添加糖液群の例について血糖値の経時変化グラフを図
1に示した。図1の斜線部分の面積が血糖値上昇面積で
ある。The blood glucose level rising area is defined by a line between the broken line of blood glucose level change in the case where the blood glucose level changes over time and a straight line parallel to the time axis passing through the point indicating the blood glucose level at the start of the test. Refers to the area. This means the total increase in blood glucose level during the test period (unit: mg / dL / 120 min). FIG. 1 shows a graph of changes in blood glucose levels over time for the examples of the betaine-added sugar solution group. The area of the shaded area in FIG. 1 is the area of increased blood glucose level.
【0020】これと全く同様の試験を20%スクロース
溶液を糖液とした表1の各投与液についても行った。こ
れらの結果については、20%グルコース溶液を糖液と
した場合の血糖値の経時変化および血糖値上昇面積を表
3および表4に、20%スクロース溶液を糖液とした場
合の血糖値の経時変化および血糖値上昇面積を表5、表
6に示した。The same test as above was carried out for each administration solution in Table 1 using a 20% sucrose solution as a sugar solution. Regarding these results, Table 3 and Table 4 show the time-dependent changes in blood glucose level and the area of increased blood glucose level when a 20% glucose solution was used as the sugar solution, and the time-dependent blood glucose levels when the 20% sucrose solution was used as the sugar solution. The changes and the areas of increased blood glucose levels are shown in Tables 5 and 6.
【0021】[0021]
【表3】 [Table 3]
【0022】[0022]
【表4】 [Table 4]
【0023】[0023]
【表5】 [Table 5]
【0024】[0024]
【表6】 [Table 6]
【0025】表3に示すとおり、ベタインの投与により
グルコースの吸収は明らかに抑制され、ベタイン添加糖
液群の血糖値は、15分目以降基本糖液群のものよりも
低い値を維持した。これに対し従来糖吸収抑制効果のあ
るといわれているペクチン、ギムネマ添加群の血糖値は
15分目に基本糖液群よりも低い値を示したが、その後
上昇し60分目、120分目には基本糖液群のものより
高い値となった。表4の血糖値上昇面積に示すとおり、
ベタイン添加群は基本糖液群よりも低い値を取った。ペ
クチン、ギムネマは基本糖液群とほぼかわらない値を示
した。また表5、表6に示すとおりこの現象は20%ス
クロースを糖液とした場合にも同様に見られた。As shown in Table 3, the glucose absorption was obviously suppressed by the administration of betaine, and the blood sugar level of the betaine-added sugar solution group remained lower than that of the basic sugar solution group after 15 minutes. On the other hand, the blood sugar level of the pectin and Gymnema-added group, which was conventionally said to have an effect of suppressing sugar absorption, was lower than that of the basic sugar solution group at 15 minutes, but then increased at 60 minutes and 120 minutes. Was higher than that of the basic sugar solution group. As shown in the blood glucose level rising area in Table 4,
The betaine addition group had a lower value than the basic sugar solution group. Pectin and Gymnema showed almost the same values as those of the basic molasses group. Further, as shown in Tables 5 and 6, this phenomenon was also observed when 20% sucrose was used as the sugar solution.
【0026】これらより、ベタインが糖吸収を抑制する
こと、従来効果があるといわれているペクチン、ギムネ
マの効果が糖吸収を遅延させるものであるのに対し、ベ
タインの効果は糖の吸収量を減らすものであることが判
った。From these, betaine suppresses sugar absorption, and the effects of pectin and Gymnema, which are said to be effective in the past, delay sugar absorption, whereas the effects of betaine increase sugar absorption. It turned out to be a reduction.
【0027】[0027]
【試験例2】 〔糖負荷試験〕8人の男性(20〜30才)を被験者と
し、耐糖性試験を行った。被験者らは試験前日夕食より
飲水のみを許し一夜絶食させた。4人づつの2つのグル
ープに組分け、500mL、16%グルコース溶液(8
0gグルコースに相当する。以下基準糖液という)また
は500mLの基準糖液にベタイン1%を添加したもの
(80gグルコースに5gベタインを加えたものに相当
する。以下ベタイン添加糖液という)をそれぞれのグル
ープの被験者に経口摂取させ、摂取後0、30、60、
90、120、150および180分に上肢正中皮静脈
から採血して遠沈管に移し、直ちに3000r.p.
m.、10分で遠心分離し、血清を取り出し、グルコー
スオキシダーゼ法で血糖値を測定した。この結果につい
ては、表7に血糖値の経時変化を示した。[Test Example 2] [Glucose tolerance test] A glucose tolerance test was conducted using 8 males (20 to 30 years old) as subjects. The test subjects allowed only drinking water from the evening before the test and fasted overnight. Divided into two groups of 4 people each, 500 mL, 16% glucose solution (8
Corresponds to 0 g glucose. Oral ingestion of 500 ml of standard sugar solution to which 1% of betaine was added (corresponding to 80 g of glucose plus 5 g of betaine; hereinafter referred to as betaine-containing sugar solution) to each group of subjects. And 0, 30, 60 after ingestion
At 90, 120, 150 and 180 minutes, blood was collected from the median dermal vein of the upper limb and transferred to a centrifuge tube, and immediately 3,000 r.p.m. p.
m. After centrifugation for 10 minutes, the serum was taken out and the blood glucose level was measured by the glucose oxidase method. Regarding this result, Table 7 shows the time-dependent changes in blood glucose level.
【0028】[0028]
【表7】 [Table 7]
【0029】表7に示した通り、ベタインの添加により
糖液投与による血糖値の上昇が抑えられ、30分目より
試験終了までベタイン添加糖液群の血糖値は基準糖液群
のものより低い血糖値を維持した。これらより、ヒトに
おいても、ベタインにより糖吸収が抑制されることが明
らかになった。As shown in Table 7, the increase in blood glucose level due to the administration of the sugar solution was suppressed by the addition of betaine, and the blood glucose level of the betaine added sugar solution group was lower than that of the reference sugar solution group from the 30th minute until the end of the test. Blood sugar level was maintained. From these results, it was revealed that betaine also suppresses sugar absorption in humans.
【0030】[0030]
【試験例3】 〔ラットの体重増加抑制効果〕5週令のSD系ラット2
0匹を用いた。AIN76組成に基づく基本飼料で1週
間予備飼育した後、1群10匹ずつ2群に組分け、基本
飼料またはこれにベタイン2%を添加した飼料を自由摂
取させた。投与開始から7、14、28、42、56日
目に体重を測定し、初期体重からの増加量を求め、群毎
に平均値を算出した。また飼料摂取量も同時に測定し
た。56日目にラットを麻酔下で解剖し、肝臓、副睾丸
脂肪組織、腎周囲脂肪組織を取り出し、重量分析に供し
た。肝臓はFolchらの方法に従い総脂質含量も分析
した。表8に体重増加及び飼料摂取量、表9に肝臓、副
睾丸脂肪組織、腎周囲脂肪組織および肝臓総脂質含量を
示した。[Test Example 3] [Effect of suppressing body weight increase in rat] SD rat 2 of 5 weeks old
0 was used. After preliminarily breeding with a basic feed based on the AIN76 composition for 1 week, 10 animals per group were divided into 2 groups, and the basic feed or a feed containing 2% betaine added thereto was freely taken. Body weights were measured 7, 14, 28, 42, and 56 days after the start of administration, the amount of increase from the initial body weight was obtained, and the average value was calculated for each group. The feed intake was also measured at the same time. On day 56, the rat was dissected under anesthesia, and the liver, epididymal adipose tissue, and perirenal adipose tissue were taken out and subjected to weight analysis. Liver was also analyzed for total lipid content according to the method of Folch et al. Table 8 shows weight gain and feed intake, and Table 9 shows liver, epididymal adipose tissue, perirenal adipose tissue and total liver lipid content.
【0031】[0031]
【表8】 [Table 8]
【0032】[0032]
【表9】 [Table 9]
【0033】試験期間中、実験動物の一般健康状態及び
行動に異常は見られず、死亡例も皆無であった。表8に
示したように、ベタイン添加飼料群では、基本飼料群に
比較して体重増加が少なかった。表9に示す通り肝臓、
副睾丸脂肪組織、腎周囲脂肪組織重量もベタイン添加飼
料群で低い傾向が見られた。肝臓の総脂質含量も有意に
低い値を示した。試験期間を通し、摂取量に有意な差は
認められなかった。During the test period, no abnormality was observed in the general health condition and behavior of the experimental animals, and there were no deaths. As shown in Table 8, in the betaine-added feed group, the weight gain was less than that in the basic feed group. Liver as shown in Table 9,
The epididymal adipose tissue and perirenal adipose tissue weights also tended to be lower in the betaine-added diet group. The total lipid content of the liver also showed a significantly low value. No significant difference was observed in the intake throughout the test period.
【0034】[0034]
【実施例1】卵3個をハンドミキサーで泡立てた。砂糖
120g、ベタイン10g、バニラエッセンス数滴、牛
乳大さじ3杯を加え軽く混ぜた。さらに小麦粉120g
を加え軽く混ぜケーキ型に流し込み、オーブンで150
℃、35分焼いた。Example 1 Three eggs were whipped with a hand mixer. 120 g of sugar, 10 g of betaine, a few drops of vanilla extract, and 3 tablespoons of milk were added and mixed gently. 120g of flour
Add lightly, pour into a cake mold and pour in an oven for 150
Baked at 35 ° C for 35 minutes.
【0035】[0035]
【実施例2】 タブレット 表10の組成を混合し、加圧成型する事によりタブレッ
トを作成した。Example 2 Tablet A tablet was prepared by mixing the compositions shown in Table 10 and molding the mixture under pressure.
【0036】[0036]
【表10】 [Table 10]
【0037】[0037]
【発明の効果】以上説明した通り、本発明の血糖値上昇
抑制剤及び血糖値上昇抑制機能性糖質食品素材は、糖と
同時摂取する事により血糖値上昇を抑えることができる
ため、カロリー過剰摂取による肥満症、高脂血症、糖尿
病の予防および治療効果を持つ製剤及び食品素材として
すぐれている。Industrial Applicability As described above, the blood sugar level increase inhibitor and the blood sugar level increase suppression functional sugar food material of the present invention can suppress the blood sugar level increase by simultaneous ingestion with sugar. It is excellent as a preparation and a food material having an effect of preventing and treating obesity, hyperlipidemia and diabetes caused by ingestion.
【図1】ベタイン添加糖液群についての血糖値の経時変
化グラフを示す図である。FIG. 1 is a diagram showing a time-dependent graph of blood glucose levels for a betaine-added sugar solution group.
Claims (3)
制剤。1. A blood sugar level elevation inhibitor containing betaine as an active ingredient.
〜30%のベタインを有効成分として含有する血糖値上
昇抑制機能性糖質食品素材。2. Carbohydrate and 0.1 to 50%, preferably 1
A functional sugar food material for suppressing an increase in blood sugar level, which comprises ~ 30% betaine as an active ingredient.
〜30%のベタインを有効成分として用いて加工乃至は
調理してなる血糖値上昇抑制機能性飲食品。3. Carbohydrate and 0.1 to 50%, preferably 1
A food or drink that is functionalized or cooked using ~ 30% betaine as an active ingredient, and is capable of suppressing an increase in blood sugar level.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30167594A JP3234113B2 (en) | 1994-11-11 | 1994-11-11 | Blood glucose elevation inhibitors and uses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30167594A JP3234113B2 (en) | 1994-11-11 | 1994-11-11 | Blood glucose elevation inhibitors and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08133970A true JPH08133970A (en) | 1996-05-28 |
| JP3234113B2 JP3234113B2 (en) | 2001-12-04 |
Family
ID=17899784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30167594A Expired - Fee Related JP3234113B2 (en) | 1994-11-11 | 1994-11-11 | Blood glucose elevation inhibitors and uses |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3234113B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005065675A1 (en) * | 2004-01-07 | 2005-07-21 | Premacs International Pty. Ltd. | Method of treatment |
| JP2009506978A (en) * | 2005-04-27 | 2009-02-19 | メッサデク ジャアル | Combination of insulins |
| EP2241197A1 (en) | 2002-11-18 | 2010-10-20 | Mitsui Sugar Co., Ltd. | Agent and edible material for inhibiting body fat accumulation |
| WO2014189328A1 (en) * | 2012-08-14 | 2014-11-27 | (주)바이오뉴트리젠 | Anti-obesity composition containing lycium chinense miller leaf extract powder and betaine as active ingredients |
| KR20180098882A (en) | 2017-02-27 | 2018-09-05 | 주식회사 솔고 바이오메디칼 | Composition for the effect of suppressing the elevation of blood sugar level having extract of peanut sprouts as active component |
-
1994
- 1994-11-11 JP JP30167594A patent/JP3234113B2/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2241197A1 (en) | 2002-11-18 | 2010-10-20 | Mitsui Sugar Co., Ltd. | Agent and edible material for inhibiting body fat accumulation |
| US9017745B2 (en) | 2002-11-18 | 2015-04-28 | Mitsui Sugar Co., Ltd. | Method of using isomaltulose to suppress body fat accumulation |
| US9017744B2 (en) | 2002-11-18 | 2015-04-28 | Mitsui Sugar Co., Ltd. | Method of using isomaltulose to suppress blood glucose level increase |
| WO2005065675A1 (en) * | 2004-01-07 | 2005-07-21 | Premacs International Pty. Ltd. | Method of treatment |
| JP2009506978A (en) * | 2005-04-27 | 2009-02-19 | メッサデク ジャアル | Combination of insulins |
| WO2014189328A1 (en) * | 2012-08-14 | 2014-11-27 | (주)바이오뉴트리젠 | Anti-obesity composition containing lycium chinense miller leaf extract powder and betaine as active ingredients |
| KR20180098882A (en) | 2017-02-27 | 2018-09-05 | 주식회사 솔고 바이오메디칼 | Composition for the effect of suppressing the elevation of blood sugar level having extract of peanut sprouts as active component |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3234113B2 (en) | 2001-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11730178B2 (en) | Extraction method | |
| ES2230573T3 (en) | ANTI-OBESITY AGENT WHOSE ACTIVE PRINCIPLE IS PROCIANIDINE. | |
| JP3530657B2 (en) | Food composition for improving blood sugar | |
| JP6621463B2 (en) | Health food composition for lowering blood glucose level and managing weight | |
| EP0930019A2 (en) | Composition for treating obesity and foods and drinks containing the same | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| WO1994012057A1 (en) | Diet sweetener | |
| JPH038188B2 (en) | ||
| JP3234113B2 (en) | Blood glucose elevation inhibitors and uses | |
| JP2006104181A (en) | Glucide-splitting enzyme-inhibiting material derived from fagaceae plant and application thereof | |
| JP2002193797A (en) | Composition for improving insulin resistance | |
| JP2001278804A (en) | Lipid metabolism-improving agent and food containing the same | |
| JPH0965836A (en) | α-Glucosidase inhibitor, sugar composition containing the same, sweetener, food and feed | |
| JP2005170836A (en) | Seaweed extract and lipase inhibitor containing the same | |
| JP2002173435A (en) | Antiobestic drug and medication method for the same | |
| JPH09104624A (en) | α-Glucosidase inhibitor, sugar-based composition containing the same, sweetener, food and feed | |
| DE2706319B2 (en) | Process for the production of sweeteners with 1-sorbose | |
| KR101166852B1 (en) | Compositions comprising Hippophae rhamnoides L. leaves or extracts thereof for amelioration of body lipid | |
| US20100173025A1 (en) | Fat absorption inhibitory composition | |
| JP2005022994A (en) | Hypoglycemic composition | |
| US20050226941A1 (en) | Composition for controlling excessive calorie intake-induced disorder, food product for controlling excessive calorie intake-induced disorder, skin preparation for external use for controlling | |
| JPH0288525A (en) | Medicine and ingesta for remedy and prevention of obesity | |
| JP4520602B2 (en) | Antihypertensive agent | |
| JP4445145B2 (en) | Oral composition | |
| JP2008050277A (en) | Composition for treating sideropenic anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080921 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090921 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100921 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100921 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110921 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120921 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120921 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130921 Year of fee payment: 12 |
|
| LAPS | Cancellation because of no payment of annual fees |